CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenues:
Patient service	$ 24,910	$ 24,517	$ 49,615	$ 48,180
Research services	5,252	479	10,124	894
Product	1,942	2,454	4,783	5,421
Total revenues	32,104	27,450	64,522	54,495
Cost of revenues:
Patient services	8,827	9,313	17,591	18,784
Research services	2,769	160	5,507	315
Product	1,012	1,251	2,383	3,060
Total cost of revenues	12,608	10,724	25,481	22,159
Gross profit	19,496	16,726	39,041	32,336
Operating expenses:
General and administrative	9,077	7,635	18,605	16,308
Sales and marketing	6,267	6,027	13,029	12,179
Bad debt expense	1,967	2,959	4,434	5,870
Research and development	1,882	1,040	3,502	2,225
Integration, restructuring and other charges	2,541	733	3,743	1,003
Total expenses	21,734	18,394	43,313	37,585
Loss from operations	(2,238)	(1,668)	(4,272)	(5,249)
Other income, net	(61)	39	(114)	86
Loss before income taxes	(2,299)	(1,629)	(4,386)	(5,163)
Income tax benefit (expense)		431		431
Net loss	(2,299)	(1,198)	(4,386)	(4,732)
Net loss per common share:
Basic and diluted (in dollars per share)	$ (0.09)	$ (0.05)	$ (0.17)	$ (0.19)
Weighted average number of common shares outstanding:
Basic and diluted (in shares)	25,537,358	24,918,996	25,370,164	24,761,904
Unrealized gains on securities:
Unrealized holding gains/(losses) arising during the period		4		12
Comprehensive Loss	$ (2,299)	$ (1,194)	$ (4,386)	$ (4,720)